CDKN2A and astrocytoma (excluding glioblastoma): There were no significant differences in survival within astrocytomas WHO grade 4 when grouping patients only by morphology or CDKN2A/B deletion (Fig. 3C-D), as well as when comparing G-CIMP high tumors to G-CIMP low (Supplementary materials Fig. 2).